Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
SCLC, Small Cell Lung Cancer

Quratusugene Ozeplasmid for Small Cell Lung Cancer Receives Orphan Drug Designation by FDA

Posted on August 21, 2023
Post Views: 398

SCLC, Small Cell Lung CancerGenprex, Inc. is a clinical-stage gene therapy company and has announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the drug, Reqorsa Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer. Earlier in June 202e, FDA granted Fast Track Designation for Reqorsa Immunogene Therapy, in combination with Tecentriq in patients with extensive-stage small cell lung cancer who did not develop tumor progression after receiving Tecentriq and chemotherapy as an initial standard treatment.

REQORSA has a plasmid that expresses a tumor suppressor gene protein and this is called TUSC2. Virtually, all of small cell lung cancers reduced or to no TUSC2 protein expression and 41% lack TUSC2 protein expression. The studies suggested that re-expressing TUSC2 protein may lead to clinical efficacy. The combination of quratusugene ozeplasmid and atezolizumab is being evaluated as a maintenance therapy in patients with ES-SCLC. REQORSA is being evaluated in three clinical trials as a treatment for non-small cell lung cancer and small cell lung cancer.

Genprex president, chairman and CEO Rodney Varner said: “This FDA orphan drug designation in combination with our recently received FDA Fast Track designation underscores the great need for better treatment options for patients with SCLC, ES-SCLC and NSCLC.” “We look forward to initiating the Acclaim-3 clinical trial expected in the fourth quarter of 2023 in order to bring hope of an effective new therapy to patients suffering with this life-limiting cancer,” he added.

ODD status is granted by FDA to investigational therapies developed to treat, diagnose or prevent a rare condition affecting less than 200,000 people in the United States. With ODD status, the drug developers receives some benefits like assistance in drug development process, waiver of certain FDA fees, tax credits for qualified trails and potential for seven years of post-approval marketing exclusivity.

The information shared in this blog is solely for educational purposes.

Subscribe to our newsletter or follow us on Facebook or Twitter today and never miss out an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,322)
  • Lung Cancer: Symptoms and Treatment (5,651)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025
  • Lung Cancer Screening Is Beneficial For Non-Smokers As Well April 28, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d